With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.
With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.
Copyright © 2024 | WordPress Theme by MH Themes